Alopecia areata (AA) is a common chronic tissue-specific autoimmune disease, resulting in
hair loss, that affects up to 2% of the general population. The exact pathobiology of AA has …

Alopecia areata (AA) is a common inflammatory autoimmune disease of the hair which can
have a significant negative impact on quality of life (QoL), mental health and productivity …

Background Alopecia areata is an autoimmune condition characterized by rapid hair loss in
the scalp, eyebrows, and eyelashes, for which treatments are limited. Baricitinib, an oral …

Background Alopecia areata is characterised by non-scarring loss of scalp, face, or body
hair. We investigated the efficacy and safety of ritlecitinib, an oral, selective dual JAK3/TEC …

Background There are no treatments approved by the Food and Drug Administration for
alopecia areata. Objective To evaluate the efficacy and safety of baricitinib in patients with≥ …

Alopecia areata (AA) is a relatively common nonscarring hairloss disease characterized by
an autoimmune response to anagen hair follicles (HFs). Accumulated evidence suggests …

Background Alopecia areata (AA) is characterized by hair loss that can affect the scalp and
body. This study describes the psychosocial burden of AA. Methods Participants diagnosed …

Alopecia areata (AA) is an autoimmune disease characterized by nonscarring hair loss. As a
clinically heterogeneous disease, various classification systems have evolved for defining its …

Background The current classification for Alopecia Areata (AA) does not provide a consistent
assessment of disease severity. Objective To develop an AA severity scale based on expert …

Management options for moderate‐to‐severe alopecia areata (AA) are limited owing to a
lack of safe and effective treatments suitable for long‐term use. However, newer agents …